IP Library › Granted Patent US 8,026,274
Granted Patent B2
US 8,026,274 · App. 10/799,197 · Granted Sep 27, 2011

Use of oxandrolone in the treatment of burns and other wounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,026,274
App. No.
10/799,197
Granted
Sep 27, 2011
Kind
B2
Abstract

The subject invention provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The invention also provides a method of treating a wound in a patient suffering from a wound which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The subject invention further provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone in conjunction with a protein supplement to the patient.

Claims (12)

1. A method of promoting weight gain after weight loss resulting from post-burn catabolism in a patient in need thereof which comprises administering to the patient 10 mg to 100 mg of oxandrolone per day in conjunction with a protein supplement to achieve a daily protein intake by the patient of approximate 2.0 g/kg/day, for a period of three weeks.

2. A method according to claim 1 wherein the amount of oxandrolone administered is about 80 mg per day.

3. A method according to claim 1 wherein the amount of oxandrolone administered is about 20 mg per day.

4. A method according to claim 1 wherein the amount of oxandrolone administered is about 10 mg per day.

5. A method according to claim 1 wherein the oxandrolone is administered orally.

6. A method according to claim 1 wherein the oxandrolone is administered topically.

7. A method according to claim 1 wherein the oxandrolone is administered by injection.

8. A method according to claim 1 wherein the oxandrolone is in a solid dosage form.

9. A method according to claim 1 wherein the oxandrolone is in a liquid dosage form.

10. A method according to claim 1 wherein the oxandrolone is in a sustained-release formulation.

11. A method according to claim 1 wherein the oxandrolone is 17α-methyl-17β-hydroxy-2-oxa-5α-androstan-3-one.

12. A method according to claim 1 wherein the weight gain comprises lean body weight gain.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Jan 13, 2016
From: FIFTH STREET FINANCE CORP., AS COLLATERAL AGENT
To: CREALTA PHARMACEUTICALS LLC
Reel/Frame 037483/0049 →
RELEASE OF SECURITY INTEREST Recorded Jan 13, 2016
From: JEFFERIES FINANCE LLC, AS COLLATERAL AGENT
To: CREALTA PHARMACEUTICALS LLC
Reel/Frame 037483/0148 →
SECURITY AGREEMENT Recorded Mar 4, 2014
From: CREALTA PHARMACEUTICALS LLC
To: FIFTH STREET FINANCE CORP., AS COLLATERAL AGENT
Reel/Frame 032384/0285 →
SECURITY AGREEMENT Recorded Feb 21, 2014
From: CREALTA PHARMACEUTICALS LLC
To: JEFFERIES FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 032319/0077 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY PREVIOUSLY RECORDED ON REEL 028363 FRAME 0040. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Jul 23, 2013
From: SAVIENT PHARMACEUTICALS, INC.
To: U.S. NATIONAL BANK ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 030936/0072 →
SECURITY AGREEMENT Recorded Jun 12, 2012
From: SAVIENT PHARMACEUTICALS, INC.
To: MORGAN STANLEY SENIOR FUNDING INC.
Reel/Frame 028363/0040 →